Parker Waichman LLP

Many FDA-Approved Drug Trial Reports Go Unpublished Causing Bias

A study conducted by University of California, San Francisco (UCSF) researchers states that selective reporting of drug clinical trials may bias comparisons to other medications.  The researchers also state that over half of all supporting clinical trials for U.S. Food and Drug Administration (FDA)-approved drugs have remained unpublished as long as five years after permission […]

A study conducted by University of California, San Francisco (UCSF) researchers states that selective reporting of drug clinical trials may bias comparisons to other medications.  The researchers also state that over half of all supporting clinical trials for U.S. Food and Drug Administration (FDA)-approved drugs have remained unpublished as long as five years after permission has been granted to sell those drugs in the United States. Study findings were published in the journal PLoS Medicine.

As part of their research, the team reviewed medical literature to determine the publication status of all 909 clinical trials that supported the 90 new drug applications that were approved by the FDA in the years between 1998 and 2000.  The group found that 76 percent of all key trials—for example, large Phase II and Phase III trials, which are designed to determine a drug’s overall risks and benefits—were published in medical journals, usually within three years of FDA approval of the drug.  Interestingly, less than half—only 43 percent—of all supporting trials submitted to the FDA were published.
The UCSF team also revealed that there were incidences of selective reporting of the results from these trials.  This means that in a key trial in which a new drug was found to have outperformed an old drug, the findings were likelier to be published than, say, results from a trial indicating that a new drug performed no better than its older counterpart.  According to the UCSF researchers, Publication biases such as this can lead to records inaccurately appearing favorable in the medical literature discussing one drug’s performance over other medications and can also lead physicians to favor newer and more expensive medications over older, proven drugs.

The UCSF researcher team says that their findings are providing a starting point with which to begin monitoring the effects of the FDA Amendments Act of 2007, which was introduced to improve accuracy and totality of drug trial reporting.  The Act also requires all trials supporting FDA-approved drugs be registered when the trials are initiated and that all such outcomes be posted within one year of drug approval on the U.S. National Institutes of Health’s (NIH) clinical trials Website.

H.R. 3580, known as the FDA Amendments Act of 2007, was signed into law October 1st and is meant to ensure that FDA staff have the additional resources needed to conduct the complex and comprehensive reviews necessary to new drugs and devices.  The amendments represent the most comprehensive overhaul of food and drug law since 1997 and include several major changes to the Federal Food, Drug, and Cosmetic Act (“FDCA”), including the reauthorization, increase, and addition of new user fees for prescription drug and device products for another five years; an increase of the FDA’s regulatory authority to monitor the safety of marketed drug products and medical devices; the addition of incentives for development and oversight of pediatric drugs and devices; and strengthening of food safety requirements.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value They helped me throughout the whole process and they worked hard for me and got a generous settlement and have additional health coverage. They communicated with me and always replied to emails, texts and calls promptly. I highly recommend them!
Giovanna Losardo
3 years ago
5 Star Reviews 150
Honestly had the best experience with Parker Waichman. Big shout out to Aurora and Jillian for all their hard work getting everything done efficiently with an amazing outcome! Highly recommended using this firm!
Greg Magno
6 months ago
5 Star Reviews 150
I speak with Joanne Stevens Nurse Consultant from Parker Waichman LLP she is a pleasure and very compasionate person. so far happy with the people and the firm..
Lona Frawley
5 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038